

Date: January 23, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Submission of statement of Deviation or Variation in utilisation of funds of public issue pursuant to Regulations 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for quarter ended on December 31, 2024.

Dear Sir/Madam,

Pursuant to Regulation 32 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, please find enclosed herewith the statement of deviation(s) or variation(s) in utilisation of funds raised through Initial Public Offer (“IPO”) by the Company for the quarter ended December 31, 2024.

We hereby confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of IPO for the abovementioned period as mentioned in the objects stated in the Prospectus dated December 24, 2024.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on January 23, 2025.

This intimation is also being uploaded on the website of the Company i.e. www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

STATEMENT OF DEVIATION(S) / VARIATION(S) IN UTILISATION OF FUNDS RAISED THROUGH IPO, FOR THE QUARTER ENDED DECEMBER 31, 2024

Name of listed entity	Senores Pharmaceuticals Limited
Mode of Fund Raising	Initial Public offer
Date of Raising Funds	December 26, 2024
Amount Raised	Rs. 500 Crores
Report filed for Quarter ended	December 31, 2024
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	CARE Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No comments
Comments of the auditors, if any	No comments

Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation	Modified Allocation, if any	Funds Utilized	Amount of Deviation/Variation for the quarter according to applicable object	Remarks, if any
Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	Not Applicable	107.00	Not Applicable	Nil	Nil	-
Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	Not Applicable	73.48	Not Applicable	Nil	Nil	-
Investment in our Subsidiary,	Not Applicable	20.22	Not Applicable	Nil	Nil	-

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263

namely, Havix, for re- payment/pre- payment in full or in part, of certain borrowings availed by such Subsidiaries						
Funding the working capital requirements of our Company	Not Applicable	43.26	Not Applicable	Nil	Nil	-
Investment in our Subsidiaries, namely, SPI to fund their working capital requirements	Not Applicable	59.48	Not Applicable	Nil	Nil	-
Investment in our Subsidiaries, namely Ratnatris to fund their working capital requirements	Not Applicable	-	Not Applicable	Nil	Nil	-
Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	Not Applicable	154.37	Not Applicable	Nil	Nil	-
Offer expenses	Not Applicable	42.19	Not Applicable	10.00	Nil	-
Total		500.00		10.00		

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fund-raising documents i.e, prospectus, letter of offer, etc

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra

Company Secretary and Compliance Officer
 ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263